In King of Prussia, Pennsylvania, on May 1, 2025, SK Life Science Labs unveiled its latest development. This subsidiary of SK Biopharmaceuticals Co., Ltd., a renowned global biotech company, specializes in creating treatments for cancer and central nervous system (CNS) disorders. The announcement marks a significant milestone for the company's mission aimed at advancing healthcare solutions.